AstraZeneca announced positive results in a late-stage trial comparing Lynparza to physician’s choice of a standard of care chemotherapy in the treatment of patients with a type of breast cancer.
Patients treated with Lynparza showed a statistically-significant improvement in progression-free survival (PFS) compared with those who received chemotherapy.
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive Phase III data for a PARP inhibitor beyond ovarian cancer. This is highly encouraging for the development of our broad portfolio which aims to treat multiple cancers by targeting DNA damage response pathways.”
Initial findings from the OLYMPIAD study indicate that the safety profile of Lynparza was consistent with previous studies.
A full evaluation of the data is ongoing, and the results will be submitted for presentation at a forthcoming medical meeting. AstraZeneca will be working with regulatory authorities to make Lynparza available to patients with this type of breast cancer.
AstraZeneca has administrative and other operations in Delaware that employ about 1,500.
